Clinical Trials Logo

Smoldering Multiple Myeloma clinical trials

View clinical trials related to Smoldering Multiple Myeloma.

Filter by:

NCT ID: NCT03301220 Recruiting - Clinical trials for Smoldering Multiple Myeloma

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Start date: November 7, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).

NCT ID: NCT03289299 Not yet recruiting - Clinical trials for Smoldering Multiple Myeloma

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

ASCENT
Start date: December 1, 2017
Phase: Phase 2
Study type: Interventional

This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Approximately 50% of patients will receive non-high dose treatment in 4 phases - induction (4 cycles), consolidation (4 cycles), intensification (4 cycles), and maintenance (12 cycles). The other 50% will receive high-dose treatment in 4 phases - induction (4 cycles), autologous stem-cell transplant (ASCT), intensification (4 cycles), and maintenance (12 cycles). Each cycle is 28 days.

NCT ID: NCT03236428 Not yet recruiting - Clinical trials for Smoldering Multiple Myeloma

Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Start date: October 31, 2017
Phase: Phase 1
Study type: Interventional

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab

NCT ID: NCT02916771 Recruiting - Clinical trials for Smoldering Multiple Myeloma

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Start date: October 2016
Phase: Phase 2
Study type: Interventional

This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.

NCT ID: NCT02903381 Recruiting - Clinical trials for Smoldering Multiple Myeloma

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Start date: October 2016
Phase: Phase 2
Study type: Interventional

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma. - Patients with smoldering multiple myeloma do not have symptoms but are at risk for progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. Patients with active multiple myeloma generally require treatment.

NCT ID: NCT02886065 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

A Study of PVX-410, a Cancer Vaccine, and Durvalumab +/- Lenalidomide for Smoldering MM

Start date: November 2016
Phase: Phase 1
Study type: Interventional

This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: - Lenalidomide - Durvalumab - PVX-410

NCT ID: NCT02726750 Recruiting - Clinical trials for Smoldering Multiple Myeloma

Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies

Start date: December 2015
Phase: N/A
Study type: Observational

The goal of this clinical research study is to find markers that might help predict why some patients with monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) develop multiple myeloma, while others do not. Markers that will be studied may include participant's age, level of proteins in blood and urine, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities.

NCT ID: NCT02603887 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

Pembrolizumab for Smoldering Multiple Myeloma (SMM)

Start date: July 20, 2016
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical research study is to learn if Keytruda (pembrolizumab) can help to control intermediate- or high-risk smoldering multiple myeloma (SMM). The safety of this drug will also be studied.

NCT ID: NCT02415413 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Start date: May 2015
Phase: Phase 2
Study type: Interventional

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation. Approximately 3 months after peripheral blood stem cell transplantation patients will receive consolidation treatment during 2 months. Subsequently patients will start maintenance treatment during 24 months. Therefore, the total duration of the treatment will be approximately 36 months.

NCT ID: NCT02279394 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

Trial of Combination of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Start date: December 2014
Phase: Phase 2
Study type: Interventional

This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.